[go: up one dir, main page]

EP2555843A1 - Procédé pour production des particules de substance active cristallines - Google Patents

Procédé pour production des particules de substance active cristallines

Info

Publication number
EP2555843A1
EP2555843A1 EP11711556A EP11711556A EP2555843A1 EP 2555843 A1 EP2555843 A1 EP 2555843A1 EP 11711556 A EP11711556 A EP 11711556A EP 11711556 A EP11711556 A EP 11711556A EP 2555843 A1 EP2555843 A1 EP 2555843A1
Authority
EP
European Patent Office
Prior art keywords
particles
active ingredient
module
suspension
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11711556A
Other languages
German (de)
English (en)
Inventor
Detlef Grawe
Sabine Gliesing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JESALIS PHARMA GmbH
Original Assignee
JESALIS PHARMA GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JESALIS PHARMA GmbH filed Critical JESALIS PHARMA GmbH
Publication of EP2555843A1 publication Critical patent/EP2555843A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0004—Crystallisation cooling by heat exchange
    • B01D9/0013—Crystallisation cooling by heat exchange by indirect heat exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0036—Crystallisation on to a bed of product crystals; Seeding
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B01D9/0054—Use of anti-solvent
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0081—Use of vibrations, e.g. ultrasound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Definitions

  • the invention relates to a method for producing crystalline active substance particles, wherein the active ingredient is crystallized from a low supersaturated suspension of the active ingredient with wet grinding, cooling and ultrasound treatment. Furthermore, the invention relates to the obtainable by this process crystalline drug particles and an apparatus for performing the method.
  • the processing properties of active ingredient particles for example their bulk density, wettability, flowability, stability, solubility properties, etc. depend on the particle size and quite considerably on the particle size distribution. To achieve the fastest possible release from drug forms poorly soluble drugs are produced as fine as possible particulate.
  • a coarser grain size is generally required, which controls the dissolution of the active substance particles within the desired time window.
  • the particle size distribution should have very narrow limits and be reproducibly generated. Also for reasons of processability or the stability of active ingredients there is a need to produce active ingredients with a coarser, but well-defined and narrow particle size distribution, wherein it is desirable that the particle size distribution is achieved directly without crystallization by subsequent process steps such as sieving and milling.
  • grinding devices for the production of fine-grained crystal particles and controlled influencing of the particle size of active substances grinding devices can be used, for example rotor-stator devices.
  • Kamahara et.al. describe in "Generation of Fine Pharmaceutical Particles via Controlled Secondary Nucleation under High Shear Enviroment during Crystallization", Organic Process Research & Development 2007, 11, pp.
  • WO 03/033097 A2 likewise describes a rotor-stator grinding device in conjunction with a precipitation reaction for producing very fine-grained particles.
  • Solution and precipitant are continuously fed via separate feeds into the rotor-stator unit and reached in the shear field of the dispersion due to the high supersaturation a high nucleation rate and thus limiting the crystal growth.
  • the methods described above are suitable for achieving the finest possible grain sizes.
  • the targeted production of coarse grains in the range average particle diameter above 10 ⁇ , in particular above 20 ⁇ , however, is problematic with these precipitation reactions in the shear field of the disperser.
  • bimodal grains with a high proportion of fines are produced by superimposing nucleation and milling effects.
  • the secondary nucleation rate and thus ultimately the particle size achieved depends on a large number of factors and thus involves risks with respect to process control and reproducibility.
  • a general problem in crystallization using wet grinding equipment such as rotor-stator systems is the enormous amount of heat of dissipation, which is usually added to the heat of the hot drug solution. Since the solubility is usually temperature dependent, this heat must be effectively removed from the system. For this purpose, correspondingly large cooling surfaces are required. Due to the over-saturation that forms naturally over these surfaces, they tend to foul. This leads to disturbances of the desired grain due to coarse particles of these crusts, blockages of the transport lines and a progressive deterioration of the heat transfer. The smaller the plant, the more serious becomes the problem of heat dissipation and fouling effects.
  • the object of the invention is to overcome the disadvantages mentioned in the prior art and to provide a crystallization process which produces a largely stable, narrow and low-agglomerate particle size distribution and can deliver high quantities of active ingredient with high efficiency and cost. Furthermore, it is an object of the invention to provide an apparatus for carrying out the method.
  • This object is achieved by a process for preparing crystalline active substance particles, wherein the active ingredient crystallizes from a supersaturated solution on the surface of particles of the active substance, wherein in a first module a suspension of active ingredient particles in a supersaturated solution of the active ingredient is subjected to wet grinding, at least one Part of the suspension of active ingredient particles cooled in a second module and simultaneously subjected to ultrasound, the second module fed with active ingredient particle suspension from the first module and the active ingredient particle suspension is returned after cooling and applying ultrasound in the first module, the suspension drug solution and optionally Supplied anti-solvent and drug particles and liquid phase are removed, and the relative supersaturation of the active ingredient in the liquid phase of the suspension, based on the total liquid phase ⁇ 90%, and the removed active substance particles have an average particle size d 50 of 10 to 500 ⁇ m.
  • the process according to the invention provides, largely independently of the physico-chemical properties of the active ingredient, crystalline microparticles which have a very narrow particle size distribution and very little agglomerated particles, thereby achieving excellent processing properties of the active substance particles obtained.
  • a device for producing crystalline active substance particles comprising a first module comprising a wet grinding device in which active ingredient particles are wet-milled in a suspension, a second module comprising a cooling device and an ultrasonic source for simultaneously cooling and applying active ingredient particle suspension Ultrasound, a supply, can be supplied to the first or second module with the drug solution and optionally antisolvent, and a discharge, can be removed with the drug particles and liquid phase from the first or second module, wherein the first and second module connected to each other in that at least part of the active ingredient particle suspension can be taken out of the first module, guided through the second module and returned to the first module.
  • a device for producing crystalline active substance particles comprising a first module comprising a wet grinding device in which active ingredient particles are wet-milled in a suspension, a second module comprising a cooling device and an ultrasonic source for simultaneously cooling and applying active ingredient particle suspension Ultrasound, a supply, can be supplied to the first or second module with the drug solution and optionally antisolvent, and
  • a module is understood to mean a device or arrangement.
  • active ingredient is understood to mean a pharmaceutical active substance, that is to say a substance which exhibits a physiological action if it is absorbed in sufficient quantity by the body of a living being, in particular a mammal, preferably a human.
  • a suspension of active ingredient particles in a supersaturated solution of the active ingredient is subjected to wet milling, whereby the particles are at least partially comminuted.
  • the production of the suspension at the beginning of the process can be carried out, for example, by addition of product powder or via a start crystallization.
  • the grain size at the beginning of the process has little effect on the subsequent particle design.
  • the active ingredient crystallizes due to the supersaturation of the offered crystal surfaces and the grinding of the active ingredient particles causes the particle sizes are limited upwards.
  • the suspension is supplied with active ingredient solution and, if appropriate, anti-caking agent and, on the other hand, active ingredient particles and liquid phase are removed.
  • the supply and removal are chosen as a function of the crystallization rate, the solvent, optionally supplied Antilosungsstoff and the concentration of the supersaturated solution so that the supersaturation remains sufficiently low, so that virtually no nucleation takes place and the crystallization almost exclusively on the surface of the already existing drug particles entry.
  • the supersaturation of the method according to the invention is thus crucial. Nucleation by accordingly high supersaturations, as desired in prior art processes to produce fine particles, should be specifically avoided.
  • the supersaturation can be described by the relative supersaturation defined as follows: relative supersaturation
  • he active ingredient concentration of active compound f is the concentration of drug in the in the liquid phase of the suspension, based on the total liquid phase, in weight percent.
  • the solubility concentration active substance f is the concentration of the active ingredient in the liquid phase in the suspension at the saturation point, based on the total liquid phase, in percent by weight.
  • the saturation point represents the maximum soluble in the thermodynamic equilibrium amount of the active ingredient in the liquid phase.
  • a relative supersaturation of 50% is present in a suspension containing in the liquid phase (supersaturated solution) 30 wt .-% dissolved active ingredient and its solubility concentration 20 wt %.
  • solubility concentration solubility limit
  • a metastable zone which extends to the supersaturation limit above which then nucleation occurs. It is preferred that the concentration of the solute in the liquid phase of the suspension remain within the metastable zone.
  • the relative supersaturation in the process according to the invention in the liquid phase of the suspension based on the total liquid phase, ⁇ 90%.
  • the presence of the active substance particles, in particular the freshly milled active substance particles with their fresh breaking edges prevents germs from forming in the solution which would increase the proportion of very small particles, which would widen or inhomogeneize the particle size distribution.
  • the relative supersaturation in the process according to the invention in the liquid phase of the suspension in the range of 5-80%, more preferably in the range of 10 to 70%. Further, it is preferred that the relative supersaturation be chosen to be within the metastable zone.
  • Suitable devices for wet grinding are dispersing apparatus and homogenizers, in particular rotor-stator grinding devices, for example colloid mills, or agitator or roll mills. Preference is given to using rotor-stator apparatus, since the proportion of very small particles can be very effectively avoided by setting a defined gap width between rotor and stator.
  • the ultrasound equipment should in particular emit a sound field that is as homogeneous as possible. The aim is to keep the cooling surface largely free of crystallizing agents.
  • the specific ultrasonic power per area must not be so high that erosion of sonotrode material and thus contamination of the product suspension occur. Surprisingly, it was found that both requirements are well met by ultrasonic tube resonators, as they are currently used only for cleaning baths.
  • the power input is preferably in the range of 50 to 500 W / L (watts per liter of suspension).
  • the power output per unit surface area of the ultrasonic tube resonator is preferably in the range of 0.5 to 5 W / cm 2 .
  • the method according to the invention can be produced very reproducible particles having a mean particle size d 50 of in the range of 10 ⁇ to 500 ⁇ .
  • the average particle size d 50 is preferably 15 to 300 ⁇ m, more preferably 20 to 200 ⁇ m, and most preferably 20 to 100 ⁇ m.
  • the lower limit is determined primarily by the pure grinding effect that generates the Najimahlvorraum without feed feed. Preference is given to a d 10 value of 5-20 ⁇ , in particular 8-18 ⁇ .
  • the particle size and the particle size distribution are determined by means of a conventional laser diffraction in a wet measurement, which provides a distribution curve of the particle sizes (system Malvern, Mastersizer E, wet measurement in cuvette).
  • d x means that x volume percent (vol.%) of the particles have a diameter smaller than the specified value. With a d 50 value of 1 ⁇ thus 50 vol .-% of the particles have a diameter smaller than 1 ⁇ (microns).
  • the d 50 value is a measure of the average (volume-average) particle diameter and is therefore also referred to as the mean particle diameter.
  • An advantage of the method according to the invention is the generation of a very narrow particle size distribution.
  • largely agglomerate-free particles are obtained. This is achieved by the synchronous opposition of destructive grinding and ultrasonic processes and constructive crystal growth.
  • the disintegration effect milling process and ultrasound
  • the crystal growth in the direction of an increase in the particle size. So very narrow particle size distributions are achieved.
  • the width of a particle size distribution (Span) is defined as follows: With the method according to the invention, chip values of ⁇ 2.0, preferably chip values ⁇ 1.5, and particularly preferably chip values ⁇ 1.3, are achieved.
  • agglomerates are largely prevented in the method according to the invention, in particular by the ultrasound and in the coarse grit range also by the energy input of the wet grinder.
  • Agglomeration factor Agglomeration factor
  • Agglomeration factor d 90 (agglomerated particles) / d 90 (non-agglomerated particles)
  • d 90 values are determined by different energy input into the sample to be examined. At high energy input present agglomerates disintegrate and the subsequent particle size determination provides the d 90 of the non-agglomerated particles.
  • This d 90 non-agglomerated particles is achieved according to the sample preparation described above for wet measurement (use of the ultrasonic sonotrode from Hielscher). Any agglomerates largely decompose into their primary particles.
  • d 90 agglomerated particles
  • 12.5 mg of sample in 25 ml of aqueous surfactant solution (0.1% Tween 80 in water, saturated with active ingredient and filtered through 0.2 ⁇ filter) for 30 seconds with an Ultra Turrax stirrer (d 8 mm, Ika ) at the lowest speed (10,000 rpm).
  • the suspension thus obtained is added dropwise to the measuring cuvette containing filtered surfactant solution with stirring until the obscuration reaches 10% and determines the particle size distribution by the above-described laser diffraction. From five measurements an average value is determined.
  • the quotient d90 (Ultra Turrax stirrer) / d90 (ultrasonic sonotrode) is a measure of the agglomeration factor. Values close to 1 indicate a low agglomeration.
  • agglomeration factors of the particles of ⁇ 1, 6, preferably ⁇ 1, 3, more preferably from 1, 0 to 1, 3 are available.
  • the agglomeration factors are generally between 2 and 3.
  • Another advantage of the process according to the invention is the high crystallinity of the available product particles.
  • highly crystalline or crystalline particles are understood to mean particles which contain no or only small amorphous fractions and are therefore predominantly crystalline.
  • the crystallinity is preferred, ie the crystalline fraction> 98% by weight.
  • the crystallinity of the active ingredient particles obtainable by the process is particularly preferably> 99.5% by weight and most preferably> 99.9% by weight.
  • the crystallinity is determined by X-ray powder diffractometry (XRPD) (device: Siemens D8, fixed sample position).
  • XRPD X-ray powder diffractometry
  • the integral intensities in the X-ray diffractogram after background correction are compared with those of a reference material.
  • This reference material may be, for example, a conventional precipitate or a product of another method of preparation of known crystallinity and granularity.
  • the crystallinity is a relative size, the degree of order compared to a reference sample characterized.
  • the ratio of the integral reflection intensities of the particle sample and the reference sample is therefore the quantitative expression for their crystallinity difference.
  • the process according to the invention can be carried out both batchwise and continuously.
  • the solution of the active ingredient and optionally anti-solvent (non-solvent) are discontinuous, i. batchwise added and product particles taken in batches, especially in the form of a suspension of product particles.
  • the suspension may be circulated in the first module, for which purpose, for example, pumps may be provided or the pumping action of the wet grinding device, in particular a rotor-stator grinding device, may be used.
  • the ratio of the volume flow in the first module to the volume flow in the second module is then preferably> 10, more preferably 10 to 100.
  • the volume of the crystallization suspension remains substantially constant, since so a particularly uniform particle size distribution can be achieved.
  • substantially constant is meant in this context that the volume of the suspension does not vary by more than 20% by volume. 1 10% by volume, in particular 95-105% by volume.
  • the solution of the active ingredient and thus also the suspension may comprise one or more solvents for the active ingredient.
  • suitable solvents are, in particular, alcohols, ketones and ethers, for example methanol, ethanol, isopropanol, acetone and diethyl ether.
  • anti-solvent water is preferably used.
  • an anti-solvent means a liquid in which the active ingredient dissolves poorly.
  • the solubility should be less than 0.5 g of active ingredient per liter of anti-solvent.
  • the suspension consists of active ingredient particles and one or more solvents and optionally one or more anti-solvents.
  • the suspension should not contain any additional shaped bodies.
  • active ingredient is crystallized from a supersaturated solution on the surface of particles of the active ingredient, wherein in a first device a suspension of active ingredient particles in a supersaturated solution of the active ingredient is wet-milling, in particular with a rotor-stator A device, a portion of the suspension is passed from the first device through a second device, cooled in the second device and simultaneously exposed to ultrasound, in particular with an ultrasonic tube resonator, then the part of the suspension is returned to the first device, and the suspension continuously drug solution and optionally anti-solvent supplied and removed drug particle suspension, so that a relative supersaturation of the active ingredient in the liquid phase of the suspension, be attracted to the entire liquid phase, of ⁇ 90% is present and the removed active substance particles have a mean particle size d 50 of 10 - 500 ⁇ .
  • the span of the removed active substance particles (product particles) is ⁇ 2 and the agglomeration
  • the crystalline active substance particles obtainable by the process according to the invention have an average particle size d 50 of 10 to 500 ⁇ and a very narrow particle size distribution and a low agglomeration factor, in particular a span of ⁇ 2.0 and an agglomeration factor of ⁇ 1, 6, wherein the span as explained above as (d 90 - d 10 ) / d 50 and the agglomeration factor are defined as d 90 (agglomerated particles) / d 90 (non-agglomerated particles).
  • the invention also relates to the use of the crystalline active substance particles described as medicaments or in therapy. Further, the invention relates to a pharmaceutical composition comprising the crystalline drug particles according to the invention.
  • the crystallization process according to the invention can be carried out in a device which is relatively simple in terms of apparatus and inexpensive.
  • the device according to the invention for producing crystalline active substance particles comprises a first module comprising a wet grinding device in which active ingredient particles are wet-milled in a suspension, and a second module comprising a cooling device and an ultrasonic source for simultaneously cooling and applying at least a portion of the active ingredient particle suspension with ultrasound having.
  • the first module may be a container, which is also referred to below as a crystallizer.
  • the wet grinding device is preferably a rotor-stator grinding device.
  • the wet grinding device may be located inside the crystallizer, eg as Ultra Turrax® Stirring bar or preferably be arranged outside the crystallizer au.
  • the Notwithstandingmahlvorraum can generate a circulation flow, so that the first module is designed as a circulation apparatus.
  • a particularly preferred embodiment is that a colloid mill with adjustable gap width is used as the rotor-stator apparatus.
  • the particle size distribution of the suspension aims at a target value, which is mainly determined by the set gap width between the rotor and stator of the colloid mill and less by their speed.
  • the device according to the invention for producing crystalline active substance particles further comprises a supply, for example a fluid line, with the active substance solution and optionally anti-solvent can be supplied to the first or second module, and a discharge, which may also be a fluid line, with the active ingredient particles and liquid phase of the first or second module can be removed.
  • a supply for example a fluid line
  • the active substance solution and optionally anti-solvent can be supplied to the first or second module
  • a discharge which may also be a fluid line, with the active ingredient particles and liquid phase of the first or second module can be removed.
  • the supply and discharge are connected to the first module.
  • the first and second modules are connected to each other, preferably by fluid lines, that at least a portion of the active ingredient particle suspension can be removed from the first module, passed through the second module and returned to the first module.
  • a pump can be provided, in particular in the fluid line between the first and second module.
  • the feed can be used to continuously feed the active substance solution (feed) into the crystallizer and to continuously feed product via the discharge. Active ingredient particle suspension are taken.
  • the continuous feed feed influences the particle size in opposite directions to the grinding process.
  • a temperature difference between the feed and the first module, in particular a crystallizer and by the feed rate such supersaturation can be set that crystal growth takes place almost exclusively on the particles of the suspension.
  • a dynamic equilibrium in terms of particle size ie a stationary operating point of the particle synthesis.
  • the supersaturation can also be adjusted by adding an antisolvent.
  • the height of the feed depends on the maximum crystal growth rate in the so-called metastable zone between the solubility limit and the supersaturation limit, without nucleation.
  • the surface-related crystal growth rate (kg / m 2 * h) as a function of the relative supersaturation and the width of the metastable zone as a function of the process conditions are very substance-specific and can be determined experimentally by methods known to the person skilled in the art.
  • the particle size distribution becomes like that primarily by the gap width between rotor and stator, the feed and the removal of particles and liquid phase, preferably in the form of an active ingredient particle suspension, controlled. In contrast to the very complex processes of primary and secondary nucleation, this process is thus better controllable in the prior art processes and it is possible to produce narrow and narrow particle size distributions in a targeted and reproducible manner.
  • the device according to the invention additionally has a control module which controls the supply of the active substance solution and optionally anti-solvent and the removal of the active ingredient particles and the liquid phase so that the relative supersaturation of the active ingredient in the liquid phase of the suspension, based on the total liquid phase, ⁇ 90%.
  • the control module may be configured as hardware and / or software or as a conventional computer.
  • the control module particularly preferably controls the supply of the active substance solution and, if appropriate, antisolvent and the removal of the active ingredient particles and the liquid phase in such a way that the relative supersaturation of the active ingredient in the liquid phase of the suspension, based on the entire liquid phase, is in the range from 5 to 80%. , more preferably in the range of 10 - 70%.
  • active substance particles and liquid phase are removed in the form of an active ingredient particle suspension, ie taken from the device.
  • the first and second modules are each circulating apparatuses and / or the ultrasound source is an ultrasonic tube resonator.
  • the joint capacity of the first and second modules does not exceed 20 L (liter), especially 10 L.
  • the cooling and sonication of the suspension in the second module which may comprise a circulation circuit is possible in different ways, as will be described in more detail below with reference to Figures 2 and 3.
  • Fig. 1 shows a light micrograph of the active substance particles according to the invention.
  • FIGS. 2 and 3 show schematic views of embodiments of the device according to the invention for producing crystalline active substance particles.
  • the device 1 for producing crystalline active substance particles according to the invention comprises a crystallizer 2, which is equipped with a heating device 3 and a stirrer 4, and a wet grinding device 5, for example a rotor-stator grinding device.
  • the wet grinding device 5 is connected via fluid lines 6 with the crystallizer 2 and leads the crystal suspension in circulation.
  • Crystallizer 2, heater 3, stirrer 4, wet grinder 5 and fluid lines 6 form the first module (M1) in this embodiment.
  • the embodiment shown further comprises a fluid line 7, is conveyed through the crystal suspension in a spiral coil 8, for example of glass tube or PTFE tube, which dips into a cooling device 9.
  • the cooling device 9 is agitated with an ultrasonic source 10.
  • an ultrasound tube resonator is schematically shown as the ultrasound source 10, which acts as homogeneously as possible on the bath with ultrasound, for example at 20-25 KHz.
  • the ultrasonic vibrations are transmitted to the interior of the spiral coil 8.
  • the suspension is returned via the fluid line 1 1 to the crystallizer 2.
  • Fluid line 7, spiral coil 8, cooling device 9, ultrasonic source 1 0 and fluid line 1 1 form the second module (M2) in this embodiment.
  • active ingredient solution is continuously fed into the crystallizer 2 and continuously removed via the discharge 13 product in the form of an active ingredient particle suspension.
  • the embodiment shown further comprises a control module S1, which controls the supply of the active substance solution and optionally antisolvent and the removal of the active ingredient particles and the liquid phase so that the relative supersaturation of the active ingredient in the liquid phase of the suspension, based on the total liquid phase, ⁇ 90% is.
  • the control module S1 can be connected to the feed 12 and the discharge 13, as illustrated in FIG. 2 with dashed lines. Via the control module S1 valves and / or pumps can be controlled.
  • the sound is applied indirectly in the embodiments shown in FIG. This excludes contamination of the suspension with sonotrode materials.
  • the heat transfer in the spiral principle is very effective and the hold up of the system is low. If, in the case of longer process times, deposits nevertheless form in some regions of the spiral inner side, these can be released by periodic rinsing operations with a smaller amount of hot solvent.
  • FIG. 3 is a modification of the device according to FIG. 2.
  • the device does not comprise a spiral coil 8 but a stirring vessel 14 with jacket cooling 15 for direct sonication with the ultrasound source 10.
  • the suspension is fed into the mixing vessel 14 near the upper level.
  • the suspension is stirred intensively near the bottom with a stirrer 16.
  • the suspension circulates slowly.
  • the extraction of the sonicated and cooled suspension via the fluid line 1 1 takes place near the bottom in such a way that the level in the sonication vessel remains as constant as possible.
  • the suspension is conveyed back into the crystallizer 2 via the line 11.
  • Fluid line 7, ultrasonic source 10, fluid line 1 1, stirred vessel 14, jacket cooling 15 and stirrer 16 form the second module (M2) in this embodiment.
  • all other product-contacting parts of the system should have at least the same temperature as prevails in the crystallizer. It is therefore advisable, in order to avoid a complex tempering, to carry out the crystallization near the ambient temperature.
  • the crystallizer wall itself should, in order to avoid crusts in the longer term, be tempered because of the higher supersaturation about 2 to 8 ° C above the crystallization temperature.
  • a particle should pass through the wet grinding device as well as the device for cooling and ultrasonic agitation as often as possible before it Product flow leaves the plant.
  • the circulation currents are adjusted so that the residence time of a particle in the crystallizer is as short as possible compared to the residence time in the entire system.
  • the residence time in the crystallizer should be less than 5 minutes, better still less than one minute, or particularly advantageously less than 20 seconds.
  • the circulation flow in the second module is advantageously chosen so that a sufficient heat dissipation at the smallest possible temperature difference between the suspension temperature in the crystallizer and in the second module is possible.
  • the feed and thus the product removal stream are adjusted so that the residence time of a particle in the entire plant is sufficient to sufficiently reduce the supersaturation in the surrounding mother liquor. For many organic active ingredients, this takes place within 10 to 60 minutes. Thus, the feed or the product withdrawal stream in the process according to the invention by a factor of 10 to 100 are smaller than the circulation streams.
  • the apparatus of FIG. 3 can of course be driven with a higher feed, since the supersaturation is better degraded because of the larger compared to Fig.2 plant hold-up.
  • the suspension taken as product stream contains largely the particles formed by growth during crystallization. Oversize grain and agglomerates are largely prevented by milling and ultrasound. Thus, in addition to a deterioration of the particle size and mother liquor inclusions, which lead to cleanliness and drying problems prevented.
  • a solubility gradient can be generated in the detergent when the filter cake is being washed. It can be carried out starting with a detergent close to the solubility in mother liquors and ending with a detergent, wherein the active ingredient is almost insoluble even at higher temperatures. 'Higher temperatures' refers to any subsequent drying process above room temperature.
  • the solubility gradient can be generated continuously or stepwise. A precipitation of active ingredient from the mother liquor by a too fast Lösigesverring réelle during the washing process must be avoided in any case.
  • the product is then dried by conventional methods known to the person skilled in the art.
  • a plant according to FIG. 2 1000 g of progesterone are introduced into a crystallizer R1 and 4000 g of acetone-water mixture with 33% by weight of water are placed in the jacketed vessel R2. Thereafter, Z2 is mixed with a colloid mill (MK module, MagicLab, Fa IKA) at 16,000 rpm and a throughput of about 400 l / h and the circulation circuit Z1 with the pumps P3 and P4 with about 60 l / h the double-walled vessel R2 is put into operation.
  • R2 is in the coat with -20 cooled and R1 heated in the jacket at 28 ° C.
  • the resonator is additionally cooled at the head by a cooling sleeve.
  • acetone-water mixture in vessel R1 is added 1000 g of progesterone. Thereafter, the tube resonator, which dips into the vessel R2, with about 300 W is turned on. After circulation for 30 minutes, a feed solution of an acetone-water mixture with 33% water and with 16 wt .-% progesterone is provided at 52 ° C and pumped via P1 with 6 l / h in the crystallizer R1. In the crystallizer, a temperature of 22-25 ° C and in the vessel R2, a temperature of 17-20 ° C is. Simultaneously with the feed feed, product suspension is taken out with P2, so that the fill levels in R1 and R2 remain constant. In the stationary regime, the relative supersaturation in the crystallizer is 15%.
  • the product suspension is filtered through a frit with acetone-water mixtures (33% water, 50% water) and air-dried.
  • acetone-water mixtures 33% water, 50% water
  • the particle size distribution, the agglomeration factor and the crystallinity of the dried product were determined as described above. The following parameters were determined:
  • the external rotor-stator apparatus with circulation circuit Z2 is replaced by an internal Ultra-Turrax stirrer and the tube resonator by a conventional US bath.
  • the crystallizer R1 500 g of acetone-water mixture are presented with 33 wt% water.
  • the Ultra Turrax 25G, Ika company
  • the circulation circuit Z1 with pump P3 that with 10 L / h suspension through a cooling coil made of PTFE tube with an inner diameter of 3 mm and one Total length of 10 m promotes that dips into the sonicator R2.
  • the sonication vessel used is an ultrasonic bath filled with approx. 5 L of water, which is tempered to approx. 5-10 with externally supplied cold water. Then the US bath is turned on. R1 is tempered in the jacket to 28 ° C. After 30 minutes of operation, a feed solution of an acetone-water mixture with 33% water and with 16 wt .-% progesterone at 52 ° C via P1 with 1, 2 l / h pumped into the crystallizer R1. In the crystallizer, a temperature of 24 to 26 ° C is established. Simultaneously with the feed feed product suspension is taken with P2, so that the level remains constant in R1. From the product stream, a suspension sample is taken after 60 minutes. The relative supersaturation in the stationary regime is 23%.
  • the product suspension is filtered off with suction through a frit, washed with acetone-water mixtures (33% water, 50% water) and air-dried.
  • acetone-water mixtures 33% water, 50% water
  • the particle size distribution, the agglomeration factor and the crystallinity of the dried product were determined as described above. The following parameters were determined:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un procédé de production de particules de substance active cristallines, selon lequel une substance active est cristallisée à partir d'une solution sursaturée sur la surface de particules de la substance active, une suspension de particules de substance active dans une solution sursaturée de la substance active étant soumise dans un premier module à un broyage humide, au moins une partie de la suspension de particules de substance active étant refroidie et soumise simultanément à l'action d'ultrasons dans un deuxième module, ce dernier étant alimenté avec la suspension de particules de substance active provenant du premier module et la suspension de particules de substance active étant ramenée dans le premier module après avoir été refroidie et soumise à l'action d'ultrasons, la solution de substance active et éventuellement des antisolvants étant chargés dans la suspension et des particules de substance active ainsi qu'une phase liquide étant prélevés, la sursaturation relative de la substance active dans la phase liquide de la suspension, par rapport à la totalité de la phase liquide, étant ≤ 90 % et les particules de substance active prélevées présentant une taille moyenne de particule d50 de 10 - 500 µm.
EP11711556A 2010-04-08 2011-03-30 Procédé pour production des particules de substance active cristallines Withdrawn EP2555843A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010003711.7A DE102010003711B4 (de) 2010-04-08 2010-04-08 Verfahren zur Herstellung kristalliner Wirkstoffpartikel
PCT/EP2011/054956 WO2011124515A1 (fr) 2010-04-08 2011-03-30 Procédé pour production des particules de substance active cristallines

Publications (1)

Publication Number Publication Date
EP2555843A1 true EP2555843A1 (fr) 2013-02-13

Family

ID=44310885

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11711556A Withdrawn EP2555843A1 (fr) 2010-04-08 2011-03-30 Procédé pour production des particules de substance active cristallines

Country Status (5)

Country Link
US (1) US9211485B2 (fr)
EP (1) EP2555843A1 (fr)
CN (1) CN102858417B (fr)
DE (1) DE102010003711B4 (fr)
WO (1) WO2011124515A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102423545A (zh) * 2011-10-21 2012-04-25 北京弘祥隆生物技术股份有限公司 用于天然产物或化学药物结晶纯化的超声结晶设备
DE102016008296B4 (de) * 2016-07-05 2020-02-20 Technische Universität Bergakademie Freiberg Verfahren und Vorrichtung zur Sonokristallisation
FI127136B (en) * 2016-11-22 2017-12-15 Lappeenrannan Teknillinen Yliopisto Ultrasonic crystallizer and ultrasonic crystal system
UA127892C2 (uk) 2017-11-07 2024-02-07 Інтервет Інтернешнл Б.В. Спосіб одержання частинок ізоксазоліну великого розміру
CN108031142A (zh) * 2017-12-13 2018-05-15 上海合全药物研发有限公司 一种简化的利用湿磨来制备大量微晶种的装置及方法
CN109382194A (zh) * 2018-11-30 2019-02-26 天津威特生物医药有限责任公司 菌体样品破碎机构
GB2599890A (en) * 2020-08-18 2022-04-20 Ashe Robert Improved loop reactor
CN113144661B (zh) * 2021-03-22 2022-11-22 无棣永利盐业有限公司 一种可筛控晶体的日晒重结晶盐打花旋卤装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090087492A1 (en) * 2006-03-14 2009-04-02 Merck & Co., Inc. Processes and Apparatuses for the Production of Crystalline Organic Microparticle Compositions by Micro-Milling and Crystallization on Micro-Seed and Their Use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3510266A (en) * 1967-03-29 1970-05-05 Merck & Co Inc Production of crystals in a fluidized bed with ultrasonic vibrations
FR2408345A1 (fr) 1976-11-30 1979-06-08 Besins Jean Louis Nouvelle composition a action anti-conceptionnelle
GB2039781A (en) 1979-01-04 1980-08-20 Energy & Minerals Res Co Ultrasonic Wet Grinder
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ES2126977T3 (es) * 1991-07-10 1999-04-01 Chiyoda Chem Eng Construct Co Procedimento para la produccion de aducto cristalino de bisfenol a y fenol.
DE19832304A1 (de) * 1998-07-17 2000-01-20 Reiner Weichert Verfahren und Vorrichtung zur Ultrafein-Mahlung von festen Materialien
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US20040187770A1 (en) 2001-10-17 2004-09-30 Calabrese Richard V. Rotor-stator apparatus and process for the formation of particles
DE10218107A1 (de) 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE10218106A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE10218110A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelhilfsstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE102005053862A1 (de) * 2005-11-04 2007-05-10 Pharmasol Gmbh Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel
ATE432714T1 (de) * 2006-08-10 2009-06-15 Bayer Schering Pharma Ag Perorale arzneiform mit dienogest und ethinylestradiol zur kontrazeption
JP5248801B2 (ja) 2007-04-11 2013-07-31 日本コークス工業株式会社 粉砕分散処理システム
US8232413B2 (en) 2007-09-12 2012-07-31 Merck Sharp & Dohme Corp. Process for the production of a crystalline glucagon receptor antagonist compound
DE102008023833B4 (de) 2008-05-14 2013-03-21 Hapila Gmbh Anordnung und Verfahren zur Herstellung von hochreinen Kristallen
AU2009272445B2 (en) * 2008-07-18 2012-11-22 Circassia Limited Process for improving crystallinity
DE102008037037A1 (de) 2008-08-08 2010-02-11 Ceramtec-Etec Gmbh Verfahren zur Herstellung einer transparenten polykristallinen Keramik
DE102008037025C5 (de) * 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090087492A1 (en) * 2006-03-14 2009-04-02 Merck & Co., Inc. Processes and Apparatuses for the Production of Crystalline Organic Microparticle Compositions by Micro-Milling and Crystallization on Micro-Seed and Their Use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2011124515A1 *

Also Published As

Publication number Publication date
US9211485B2 (en) 2015-12-15
WO2011124515A1 (fr) 2011-10-13
DE102010003711A1 (de) 2011-10-13
US20130040141A1 (en) 2013-02-14
CN102858417A (zh) 2013-01-02
DE102010003711B4 (de) 2015-04-09
CN102858417B (zh) 2015-04-29

Similar Documents

Publication Publication Date Title
DE102010003711B4 (de) Verfahren zur Herstellung kristalliner Wirkstoffpartikel
DE102008037025B4 (de) Kristalline Wirkstoff-Mikropartikel, Verfahren zu deren Herstellung und Verwendung in Arzneimitteln
DE60210794T2 (de) Rotor-stator apparat und verfahren zur bildung von partikeln
DE60029457T2 (de) Verfahren zur herstellung von feinkörnigen medizinischen substanzen
EP1868573B1 (fr) Procede de production de suspensions de l'ordre du micron ultrafines
DE60117873T2 (de) Verfahren zur herstellung von submikropartikel-suspensionen pharmazeutischer substanzen
EP1286737B1 (fr) Dispositif pour la production de cristaux
EP1281420B1 (fr) Processus de crystallisation faisant appel aux ultrasons
DE102008029050A1 (de) Verfahren und Vorrichtung zur kontinuierlichen Herstellung eines Kristallisats mit konstanter Korngrößenverteilung
DE60008508T9 (de) Agglomerate durch kristallisation
DE2744802B2 (de) Verfahren zur Herstellung von AIuminhimflocken sowie Vorrichtung zur Durchführung des Verfahrens
DE69922647T2 (de) Verfahren zur herstellung einer kristallsuspension
EP1497308B1 (fr) Procede de production de cristaux de steroides, cristaux obtenus selon ce procede et utilisation de ces cristaux dans des formulations pharmaceutiques
DE10123073A1 (de) Verfahren zur Herstellung von Kristallen aus in einem Lösungsmittel gelösten Feststoffen
DE10218110A1 (de) Verfahren zum Herstellen von Kristallen von Arzneimittelhilfsstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE69521110T2 (de) Crystallisierung vom Alpha-L-Aspartyl-L-phenylalanylmethylester aus wässrigen Lösungen
DE10218106A1 (de) Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE102012221219B4 (de) Verfahren zur Vergrößerung der Partikelgröße kristalliner Wirkstoff-Mikropartikel
DE10249336A1 (de) Verfahren zur Herstellung von sprühgetrocknetem Sorbitol
WO2000007685A1 (fr) Procede de production de particules spheriques par cristallisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120913

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20130813

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20161018